Loring Wolcott & Coolidge Fiduciary Advisors LLP Bio N Tech Se Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.1 Billion
- Q2 2025
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Bio N Tech Se stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 190 shares of BNTX stock, worth $20,043. This represents 0.0% of its overall portfolio holdings.
Number of Shares
190
Previous 190
-0.0%
Holding current value
$20,043
Previous $17,000
17.65%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BNTX
# of Institutions
320Shares Held
40.9MCall Options Held
1.38MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$848 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$446 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$422 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$380 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$200 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.6B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...